

## Information for Colorado Prescribers of Prescription Drugs

### BRIUMVI™ (ublituximab-xiiy)

Colorado Revised Statutes Section 12-280-308 requires prescription drug manufacturers to disclose in writing to Colorado prescribers the Wholesale Acquisition Cost (“WAC”) of marketed drugs when engaging in prescription drug marketing.

The prices listed below represent the Wholesale Acquisition Costs (“WAC”) established and made available to the public by a third-party publisher. WAC does not reflect discounts, rebates and other reductions in price. The price paid by patients may be higher or lower than the prices listed below and is dependent on the individual patient’s insurance coverage.

**Marketed Product: BRIUMVI 150mg/6mL injection for IV**

**WAC\*: \$9,833.33**

**Package Size: 1 Vial**

Colorado law also requires manufacturers to provide the names of generic prescription drugs from the same “therapeutic class” as the marketed products. Colorado defines “therapeutic class” as “a group of similar drugs that have the same or similar mechanisms of action and are used to treat a specific condition.” The following generic prescription drugs are in the same “therapeutic class” (based on the definition of “therapeutic class” under Colorado law) as the listed TG Therapeutics product:

**Generics\*\*:** None

This information is also available at

<https://www.tgtherapeutics.com/wp-content/uploads/2022/12/Colorado-Declaration-FINAL.pdf>

For more information on the price disclosure requirements, please contact the Colorado State Board of Pharmacy’s office. Contact information can be found at <https://dpo.colorado.gov/Pharmacy>.

\* WAC price as of December 28, 2022.

\*\*This list does not imply that the products are interchangeable or have the same efficacy or safety. Please refer to each product’s FDA-approved label and indication for further information.

BRIUMVI is a trademark of TG Therapeutics, Inc.

Last updated: December 28, 2022.